<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>D.H.E. 45- dihydroergotamine mesylate injection, solution </strong><br>Valeant Pharmaceuticals North America<br></p></div>
<h1>
<span class="Bold">D.H.E. 45<span class="Sup">®</span></span><br><span class="Bold"> (dihydroergotamine mesylate)</span><br><span class="Bold"> Injection, USP</span>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d5623bfa-bd14-421c-acf9-f217b0bd793e"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
<p>Prescribing Information</p>
</div>
<div class="Warning">
<a name="box"></a><a name="section-2"></a><p></p>
<h1>WARNING</h1>
<p class="First"><span class="Bold">Serious and/or life-threatening <span class="product-label-link" type="condition" conceptid="4124836" conceptname="Peripheral ischemia">peripheral ischemia</span> has been associated with the coadministration of DIHYDROERGOTAMINE with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. Because CYP 3A4 inhibition elevates the serum levels of DIHYDROERGOTAMINE, the risk for <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> leading to <span class="product-label-link" type="condition" conceptid="374384" conceptname="Cerebral ischemia">cerebral ischemia</span> and/or <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> of the extremities is increased. Hence, concomitant use of these medications is contraindicated. <span class="Italics">(See also <a href="#contra">CONTRAINDICATIONS</a> and <a href="#warn">WARNINGS</a> section)</span></span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_4db94fe7-3941-44eb-b65a-fa4185fd0fe7"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">D.H.E. 45<span class="Sup">®</span> is ergotamine hydrogenated in the 9, 10 position as the mesylate salt. D.H.E. 45<span class="Sup">®</span> is known chemically as ergotaman-3´,6´,18-trione,9,10-dihydro-12´-hydroxy-2´-methyl-5´-(phenylmethyl)-,(5´α)-, monomethanesulfonate. Its molecular weight is 679.80 and its empirical formula is C<span class="Sub">33</span>H<span class="Sub">37</span>N<span class="Sub">5</span>O<span class="Sub">5</span>•CH<span class="Sub">4</span>O<span class="Sub">3</span>S.</p>
<p>The chemical structure is</p>
<div class="Figure">
<a name="id250"></a><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fe826e6a-75c8-43ed-9c36-f8263ec35aff&amp;name=dhe45-01.jpg">
</div>
<table width="100%">
<col width="100%">
<tbody class="Headless"><tr class="First Last"><td class="Botrule Toprule"><p class="First">Dihydroergotamine mesylate<br>C<span class="Sub">33</span>H<span class="Sub">37</span>N<span class="Sub">5</span>O<span class="Sub">5</span>•CH<span class="Sub">4</span>O<span class="Sub">3</span>S              Mol. wt. 679.80</p></td></tr></tbody>
</table>
<p>D.H.E. 45 (dihydroergotamine mesylate) Injection, USP is a clear, colorless solution supplied in sterile ampuls for intravenous, intramuscular, or subcutaneous administration. Each mL contains 1 mg Dihydroergotamine Mesylate, USP; Alcohol, USP 6.1% by volume; Glycerin, USP 15% by weight; Water for injection, USP; Methanesulfonic Acid and/or Sodium Hydroxide for pH adjustment. pH range is 3.4 - 4.9.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_86a2a273-426b-41da-a4cd-64f51a613334"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID_9231b836-ac7c-4b9b-9b7c-4226b720b1af"></a><a name="section-3.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">Dihydroergotamine binds with high affinity to 5-HT<span class="Sub">1D</span>α and 5-HT<span class="Sub">1D</span>β receptors. It also binds with high affinity to serotonin 5-HT<span class="Sub">1A</span>, 5-HT<span class="Sub">2A</span>, and 5-HT<span class="Sub">2C </span>receptors, noradrenaline α<span class="Sub">2A</span>, α<span class="Sub">2B</span> and α<span class="Sub">1</span> receptors, and dopamine D<span class="Sub">2L</span> and D<span class="Sub">3</span> receptors.</p>
<p>The therapeutic activity of dihydroergotamine in <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> is generally attributed to the agonist effect at 5-HT<span class="Sub">1D</span> receptors. Two current theories have been proposed to explain the efficacy of 5-HT<span class="Sub">1D</span> receptor agonists in <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>. One theory suggests that activation of 5-HT<span class="Sub">1D</span> receptors located on intracranial blood vessels, including those on arterio-venous anastomoses, leads to <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span>, which correlates with the relief of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span>. The alternative hypothesis suggests that activation of 5-HT<span class="Sub">1D</span> receptors on sensory nerve endings of the trigeminal system results in the inhibition of pro-inflammatory neuropeptide release.</p>
<p>In addition, dihydroergotamine possesses oxytocic properties. (<span class="Italics">See <a href="#contra">CONTRAINDICATIONS</a>.</span>)</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_749d12e1-b327-427d-8c0c-d4ea29a21db7"></a><a name="section-3.2"></a><p></p>
<h2>Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_82b25d3e-ba07-423c-bcdf-38f5e6f920aa"></a><a name="section-3.2.1"></a><p></p>
<h3><span class="Bold">Absorption</span></h3>
<p class="First">Absolute bioavailability for the subcutaneous and intramuscular route have not been determined, however, no difference was observed in dihydroergotamine bioavailability from intramuscular and subcutaneous doses.</p>
<p>Dihydroergotamine mesylate is poorly bioavailable following oral administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a4a6d225-c34e-4056-8125-d721ebdf300f"></a><a name="section-3.2.2"></a><p></p>
<h3><span class="Bold">Distribution</span></h3>
<p class="First">Dihydroergotamine mesylate is 93% plasma protein bound. The apparent steady-state volume of distribution is approximately 800 liters.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e1d92496-52e7-42f0-a194-6398fa1972a8"></a><a name="section-3.2.3"></a><p></p>
<h3><span class="Bold">Metabolism</span></h3>
<p class="First">Four dihydroergotamine mesylate metabolites have been identified in human plasma following oral administration. The major metabolite, 8´-β-hydroxydihydroergotamine, exhibits affinity equivalent to its parent for adrenergic and 5-HT receptors and demonstrates equivalent potency in several venoconstrictor activity models, <span class="Italics">in vivo</span> and <span class="Italics">in vitro.</span> The other metabolites, i.e., dihydrolysergic acid, dihydrolysergic amide, and a metabolite formed by oxidative opening of the proline ring are of minor importance. Following nasal administration, total metabolites represent only 20%-30% of plasma AUC. Quantitative pharmacokinetic characterization of the four metabolites has not been performed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_600b5e8e-850b-49d8-b8d4-db04190e9075"></a><a name="section-3.2.4"></a><p></p>
<h3><span class="Bold">Excretion</span></h3>
<p class="First">The major excretory route of dihydroergotamine is via the bile in the feces. The total body clearance is 1.5 L/min which reflects mainly hepatic clearance. Only 6%-7% of unchanged dihydroergotamine is excreted in the urine after intramuscular injection. The renal clearance (0.1 L/min) is unaffected by the route of dihydroergotamine administration. The decline of plasma dihydroergotamine after intramuscular or intravenous administration is multi-exponential with a terminal half-life of about 9 hours.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_fe020c98-0e86-4445-b729-24a6f5c4cd2d"></a><a name="section-3.2.5"></a><p></p>
<h3><span class="Bold">Subpopulations</span></h3>
<p class="First">No studies have been conducted on the effect of renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, gender, race, or ethnicity on dihydroergotamine pharmacokinetics. D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP is contraindicated in patients with severely impaired hepatic or renal function (<span class="Italics">See <a href="#contra">CONTRAINDICATIONS</a>.</span>)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_0acd8efb-ffed-452a-8ae7-eb16476539f7"></a><a name="section-3.2.6"></a><p></p>
<h3><span class="Bold">Interactions</span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">Pharmacokinetic interactions</span> have been reported in patients treated orally with other ergot alkaloids (e.g., increased levels of ergotamine) and macrolide antibiotics, principally troleandomycin, presumably due to inhibition of cytochrome P450 3A metabolism of the alkaloids by troleandomycin. Dihydroergotamine has also been shown to be an inhibitor of cytochrome P450 3A catalyzed reactions and rare reports of <span class="product-label-link" type="condition" conceptid="4201303" conceptname="Ergotism">ergotism</span> have been obtained from patients treated with dihydroergotamine and macrolide antibiotics (e.g., troleandomycin, clarithromycin, erythromycin), and in patients treated with dihydroergotamine and protease inhibitors (e.g. ritonavir), presumably due to inhibition of cytochrome P450 3A metabolism of ergotamine (<span class="Italics">See <a href="#contra">CONTRAINDICATIONS</a></span>). No <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> involving other cytochrome P450 isoenzymes are known.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_55480d01-e2ae-4c4e-8286-7624caea8b3a"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP is indicated for the acute treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span> with or without <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span> and the acute treatment of <span class="product-label-link" type="condition" conceptid="381278" conceptname="Cluster headache">cluster headache</span> episodes.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="contra"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">There have been a few reports of serious adverse events associated with the coadministration of dihydroergotamine and potent CYP 3A4 inhibitors, such as protease inhibitors and macrolide antibiotics, resulting in <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> that led to <span class="product-label-link" type="condition" conceptid="374384" conceptname="Cerebral ischemia">cerebral ischemia</span> and/or <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> of the extremities. The use of potent CYP 3A4 inhibitors (ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin, troleandomycin, ketoconazole, itraconazole) with dihydroergotamine is, therefore contraindicated (<span class="Italics">See <a href="#wcyp">WARNINGS: CYP 3A4 Inhibitors</a></span>).</p>
<p>D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP should not be given to patients with <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span> (<span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, or documented silent <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>) or to patients who have clinical symptoms or findings consistent with coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> including Prinzmetal's <span class="product-label-link" type="condition" conceptid="315830" conceptname="Prinzmetal angina">variant angina</span>. (<span class="Italics">See <a href="#warn">WARNINGS</a></span>.)</p>
<p>Because D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP may increase blood pressure, it should not be given to patients with <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncontrolled hypertension</span>.</p>
<p>D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP, 5-HT<span class="Sub">1</span> agonists (e.g., sumatriptan), ergotamine-containing or ergot-type medications or methysergide should not be used within 24 hours of each other.</p>
<p>D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP should not be administered to patients with hemiplegic or basilar <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>.</p>
<p>In addition to those conditions mentioned above, D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP is also contraindicated in patients with known peripheral arterial disease, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, following vascular surgery and severely impaired hepatic or renal function.</p>
<p>D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP may cause fetal harm when administered to a pregnant woman. Dihydroergotamine possesses oxytocic properties and, therefore, should not be administered during pregnancy. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.</p>
<p>There are no adequate studies of dihydroergotamine in human pregnancy, but developmental toxicity has been demonstrated in experimental animals. In embryo-fetal development studies of dihydroergotamine mesylate nasal spray, intranasal administration to pregnant rats throughout the period of organogenesis resulted in decreased fetal body weights and/or skeletal ossification at doses of 0.16 mg/day (associated with maternal plasma dihydroergotamine exposures [AUC] approximately 0.4-1.2 times the exposures in humans receiving the MRDD of 4 mg) or greater. A no effect level for embryo-fetal toxicity was not established in rats. Delayed skeletal ossification was also noted in rabbit fetuses following intranasal administration of 3.6 mg/day (maternal exposures approximately 7 times human exposures at the MRDD) during organogenesis. A no effect level was seen at 1.2 mg/day (maternal exposures approximately 2.5 times human exposures at the MRDD).</p>
<p>When dihydroergotamine mesylate nasal spray was administered intranasally to female rats during pregnancy and lactation, decreased body weights and impaired reproductive function (decreased mating indices) were observed in the offspring at doses of 0.16 mg/day or greater. A no effect level was not established. Effects on development occurred at doses below those that produced evidence of significant maternal toxicity in these studies.</p>
<p>Dihydroergotamine-induced <span class="product-label-link" type="condition" conceptid="80204" conceptname="Fetal growth restriction">intrauterine growth retardation</span> has been attributed to reduced uteroplacental blood flow resulting from prolonged <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span> of the uterine vessels and/or increased myometrial tone.</p>
<p>D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP is contraindicated in patients who have previously shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to ergot alkaloids.</p>
<p>Dihydroergotamine mesylate should not be used by nursing mothers. (<span class="Italics">See <a href="#precau">PRECAUTIONS</a>.</span>)</p>
<p>Dihydroergotamine mesylate should not be used with peripheral and central vasoconstrictors because the combination may result in additive or synergistic elevation of blood pressure.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="warn"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP should only be used where a clear diagnosis of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span> has been established.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="wcyp"></a><a name="section-6.1"></a><p></p>
<h2>CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors)</h2>
<p class="First">There have been rare reports of serious adverse events in connection with the coadministration of dihydroergotamine and potent CYP 3A4 inhibitors, such as protease inhibitors and macrolide antibiotics, resulting in <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> that led to <span class="product-label-link" type="condition" conceptid="374384" conceptname="Cerebral ischemia">cerebral ischemia</span> and/or and <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> of the extremities.  The use of potent CYP 3A4 inhibitors with dihydroergotamine should therefore be avoided (<span class="Italics">see <a href="#contra">CONTRAINDICATIONS</a></span>). Examples of some of the more potent CYP 3A4 inhibitors include: anti-fungals ketoconazole and itraconazole, the protease inhibitors ritonavir, nelfinavir, and indinavir, and macrolide antibiotics erythromycin, clarithromycin, and troleandomycin. Other less potent CYP 3A4 inhibitors should be administered with caution. Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. These lists are not exhaustive, and the prescriber should consider the effects on CYP 3A4 of other agents being considered for concomitant use with dihydroergotamine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="wfibrotic"></a><a name="section-6.2"></a><p></p>
<h2>Fibrotic Complications</h2>
<p class="First">There have been reports of pleural and <span class="product-label-link" type="condition" conceptid="4176725" conceptname="Retroperitoneal fibrosis">retroperitoneal fibrosis</span> in patients following prolonged daily use of injectable dihydroergotamine mesylate. Rarely, prolonged daily use of other ergot alkaloid drugs has been associated with cardiac valvular <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span>. Rare cases have also been reported in association with the use of injectable dihydroergotamine mesylate; however, in those cases, patients also received drugs known to be associated with cardiac valvular <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span>.</p>
<p>Administration of D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP, should not exceed the dosing guidelines and should not be used for chronic daily administration (<span class="Italics">see <a href="#dosage">DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_055fb168-da12-497f-bbdd-a70cb8469c58"></a><a name="section-6.3"></a><p></p>
<h2>Risk of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial Ischemia</span> and/or <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">Infarction</span> and Other Adverse Cardiac Events</h2>
<p class="First">D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP should not be used by patients with documented ischemic or vasospastic <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>. (<span class="Italics">See <a href="#contra">CONTRAINDICATIONS</a></span>.) It is strongly recommended that D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP not be given to patients in whom unrecognized <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> (CAD) is predicted by the presence of risk factors (e.g., <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, smoker, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, strong family history of CAD, females who are surgically or physiologically postmenopausal, or males who are over 40 years of age) unless a cardiovascular evaluation provides satisfactory clinical evidence that the patient is reasonably free of coronary artery and ischemic myocardial disease or other significant underlying cardiovascular disease. The sensitivity of cardiac diagnostic procedures to detect cardiovascular disease or predisposition to coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> is modest, at best. If, during the cardiovascular evaluation, the patient's medical history or electrocardiographic investigations reveal findings indicative of or consistent with coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> or <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>, D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP should not be administered. (<span class="Italics">See <a href="#contra">CONTRAINDICATIONS</a></span>.)</p>
<p>For patients with risk factors predictive of CAD who are determined to have a satisfactory cardiovascular evaluation, it is strongly recommended that administration of the first dose of D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate)</p>
<p>Injection, USP take place in the setting of a physician's office or similar medically staffed and equipped facility unless the patient has previously received dihydroergotamine mesylate. Because <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">cardiac ischemia</span> can occur in the absence of clinical symptoms, consideration should be given to obtaining on the first occasion of use an electrocardiogram (ECG) during the interval immediately following D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP, in those patients with risk factors.</p>
<p>It is recommended that patients who are intermittent long-term users of D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP and who have or acquire risk factors predictive of CAD, as described above, undergo periodic interval cardiovascular evaluation as they continue to use D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) injection, USP.</p>
<p>The systematic approach described above is currently recommended as a method to identify patients in whom D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP may be used to treat <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span> with an acceptable margin of cardiovascular safety.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ca8635ea-41e8-4138-8c50-cff1d12a32bf"></a><a name="section-6.4"></a><p></p>
<h2>Cardiac Events and Fatalities</h2>
<p class="First">The potential for adverse cardiac events exists. Serious adverse cardiac events, including <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span>, life-threatening disturbances of cardiac rhythm, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been reported to have occurred following the administration of dihydroergotamine mesylate injection. Considering the extent of use of dihydroergotamine mesylate in patients with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, the incidence of these events is extremely low.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_26c66d24-4a5e-4e4f-aa7e-38893ff3110d"></a><a name="section-6.5"></a><p></p>
<h2>Drug-Associated Cerebrovascular Events and Fatalities</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">Cerebral hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="432923" conceptname="Subarachnoid hemorrhage">subarachnoid hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, and other cerebrovascular events have been reported in patients treated with D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP; and some have resulted in fatalities. In a number of cases, it appears possible that the cerebrovascular events were primary, the D.H.E.45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP having been administered in the incorrect belief that the symptoms experienced were a consequence of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, when they were not. It should be noted that patients with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> may be at increased risk of certain cerebrovascular events (e.g., <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, transient ischemic attack).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_08b48b7d-1175-4c00-b4e9-ef17749e9495"></a><a name="section-6.6"></a><p></p>
<h2>Other <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">Vasospasm</span> Related Events</h2>
<p class="First">D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP, like other ergot alkaloids, may cause vasospastic reactions other than coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span>. Myocardial, peripheral vascular, and colonic <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> have been reported with D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP.</p>
<p>D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP associated vasospastic phenomena may also cause <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pains</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4276665" conceptname="Feels cold">coldness</span>, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>, and <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span> of the digits. In patients with compromised circulation, persistent <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> may result in <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">gangrene</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP should be discontinued immediately if signs or symptoms of <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span> develop.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5e4af359-1f5b-4bdd-a98b-cd273fb412be"></a><a name="section-6.7"></a><p></p>
<h2>Increase In Blood Pressure</h2>
<p class="First">Significant elevation in blood pressure has been reported on rare occasions in patients with and without a history of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> treated with dihydroergotamine mesylate injection. D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncontrolled hypertension</span>. (<span class="Italics">See <a href="#contra">CONTRAINDICATIONS</a></span>.)</p>
<p>An 18% increase in mean pulmonary artery pressure was seen following dosing with another 5-HT<span class="Sub">1</span> agonist in a study evaluating subjects undergoing cardiac catheterization.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="precau"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="ID_00ce197c-075b-474d-b002-f47eada7e12b"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP may cause coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span>; patients who experience signs or symptoms suggestive of angina following its administration should, therefore, be evaluated for the presence of CAD or a predisposition to <span class="product-label-link" type="condition" conceptid="315830" conceptname="Prinzmetal angina">variant angina</span> before receiving additional doses. Similarly, patients who experience other symptoms or signs suggestive of decreased arterial flow, such as ischemic bowel syndrome or Raynaud's syndrome following the use of any 5-HT agonist are candidates for further evaluation. (See <a href="#warn">WARNINGS</a>.)</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_36733478-7738-4ba8-a45a-81bdf616cec1"></a><a name="section-7.1.1"></a><p></p>
<h3><span class="Bold">Fibrotic Complications</span></h3>
<p class="First">see WARNINGS: <span class="Italics"><a href="#wfibrotic">Fibrotic Complications</a></span></p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_d4acafe7-6014-4781-8225-9251739e9023"></a><a name="section-7.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">The text of a patient information sheet is printed at the end of this insert. To assure safe and effective use of D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP, the information and instructions provided in the patient information sheet should be discussed with patients.</p>
<p>Patients should be advised to report to the physician immediately any of the following: <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> or <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> in the fingers and toes, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span> in the arms and legs, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> in the legs, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the chest, temporary speeding or slowing of the heart rate, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, or <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>.</p>
<p>Prior to the initial use of the product by a patient, the prescriber should take steps to ensure that the patient understands how to use the product as provided. (See Patient Information Sheet and product packaging.)</p>
<p>Administration of D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection USP, should not exceed the dosing guidelines and should not be used for chronic daily administration (<span class="Italics">see <a href="#dosage">DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_029a90f4-412d-4f53-a9b3-fcb61447fdc9"></a><a name="section-7.3"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e5d53ec2-b6a4-4306-abfe-f06edc8a0656"></a><a name="section-7.3.1"></a><p></p>
<h3><span class="Bold">Vasoconstrictors</span></h3>
<p class="First">D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e95ba058-2c3e-4fba-beec-ca6d47cc63bc"></a><a name="section-7.3.2"></a><p></p>
<h3><span class="Bold">Sumatriptan</span></h3>
<p class="First">Sumatriptan has been reported to cause coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span>, and its effect could be additive with D.H.E. 45<span class="Sup">® </span>(dihydroergotamine mesylate) Injection, USP. Sumatriptan and D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP should not be taken within 24 hours of each other. (<span class="Italics">See <a href="#contra">CONTRAINDICATIONS</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c8d1996e-c55e-4da2-8147-454569bce806"></a><a name="section-7.3.3"></a><p></p>
<h3><span class="Bold">Beta Blockers</span></h3>
<p class="First">Although the results of a clinical study did not indicate a safety problem associated with the administration of D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_20068d22-bc96-4c48-bbd1-877edb78086a"></a><a name="section-7.3.4"></a><p></p>
<h3><span class="Bold">Nicotine</span></h3>
<p class="First">Nicotine may provoke <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span> in some patients, predisposing to a greater ischemic response to ergot therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_baebf0ba-c2b2-429e-89dc-089b81e04d7b"></a><a name="section-7.3.5"></a><p></p>
<h3><span class="Bold">CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors)</span></h3>
<p class="First"><span class="Italics"> See <a href="#contra">CONTRAINDICATIONS</a> and <a href="#warn">WARNINGS</a>.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f1d733c6-889d-4f10-9f33-42958faeb480"></a><a name="section-7.3.6"></a><p></p>
<h3><span class="Bold">SSRI's</span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, and <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span> have been reported rarely when 5-HT<span class="Sub">1</span> agonists have been co-administered with SSRI's (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline). There have been no reported cases from spontaneous reports of drug interaction between SSRI's and D.H.E. 45<span class="Sup">® </span>(dihydroergotamine mesylate) Injection, USP.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e0103e50-af3a-44e4-9bae-79cfd236455e"></a><a name="section-7.3.7"></a><p></p>
<h3><span class="Bold">Oral Contraceptives</span></h3>
<p class="First">The effect of oral contraceptives on the pharmacokinetics of D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP has not been studied.</p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_9367e7cb-6695-4bb6-a573-5875d20e4a66"></a><a name="section-7.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_1861431e-fa03-488a-b583-fc8eee93b795"></a><a name="section-7.4.1"></a><p></p>
<h3><span class="Bold">Carcinogenesis</span></h3>
<p class="First">Assessment of the carcinogenic potential of dihydroergotamine mesylate in mice and rats is ongoing.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e3863d34-a807-4b38-ae19-4d68b89e3178"></a><a name="section-7.4.2"></a><p></p>
<h3><span class="Bold">Mutagenesis</span></h3>
<p class="First">Dihydroergotamine mesylate was clastogenic in two <span class="Italics">in vitro</span> chromosomal aberration assays, the V79 Chinese hamster cell assay with metabolic activation and the cultured human peripheral blood lymphocyte assay. There was no evidence of mutagenic potential when dihydroergotamine mesylate was tested in the presence or absence of metabolic activation in two gene mutation assays (the Ames test and the <span class="Italics">in vitro</span> mammalian Chinese hamster V79/HGPRT assay) and in an assay for DNA damage (the rat hepatocyte unscheduled DNA synthesis test). Dihydroergotamine was not clastogenic in the <span class="Italics">in vivo</span> mouse and hamster micronucleus tests.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c3d638d2-2d97-4e1a-8189-2093db9455da"></a><a name="section-7.4.3"></a><p></p>
<h3><span class="Bold">Impairment of Fertility</span></h3>
<p class="First">Impairment of fertility was not evaluated for D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP. There was no evidence of impairment of fertility in rats given intranasal doses of Migranal<span class="Sup">®</span> Nasal Spray up to 1.6 mg/day (associated with mean plasma dihydroergotamine mesylate exposures [AUC] approximately 9 to 11 times those in humans receiving the MRDD of 4 mg).</p>
</div>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_3c26e0b5-306f-40e4-bc83-5e23104f8837"></a><a name="section-7.5"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="ID_7a2db81a-ea2a-43c3-bce6-7d5b3ee619a9"></a><a name="section-7.5.1"></a><p></p>
<h3><span class="Bold">Pregnancy Category X</span></h3>
<p class="First"><span class="Italics">See <a href="#contra">CONTRAINDICATIONS</a>.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_892f993b-545c-4a3b-a04e-687261e0bbda"></a><a name="section-7.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Ergot drugs are known to inhibit prolactin. It is likely that D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP is excreted in human milk, but there are no data on the concentration of dihydroergotamine in human milk. It is known that ergotamine is excreted in breast milk and may cause <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, weak pulse, and unstable blood pressure in nursing infants. Because of the potential for these serious adverse events in nursing infants exposed to D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP, nursing should not be undertaken with the use of D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP. (<span class="Italics">See <a href="#contra">CONTRAINDICATIONS</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_120e310c-6cc1-4550-b363-f7507f4af863"></a><a name="section-7.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_bb2c25df-5f1f-4d5e-a169-577da99ab310"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Serious cardiac events, including some that have been fatal, have occurred following use of D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP, but are extremely rare. Events reported have included coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span>, transient <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>, and <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span>. (See <a href="#contra">CONTRAINDICATIONS</a>, <a href="#warn">WARNINGS</a>, and <a href="#precau">PRECAUTIONS</a>.). Fibrotic complications have been reported in association with long term use of injectable dihydroergotamine mesylate (<span class="Italics">See <a href="#wfibrotic">WARNINGS: Fibrotic Complications</a></span>).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c54e37cd-9290-469c-b271-188af197e00a"></a><a name="section-8.1"></a><p></p>
<h2>Post-introduction Reports</h2>
<p class="First">The following events derived from postmarketing experience have been occasionally reported in patients receiving D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP: <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paraesthesia</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, and pleural and <span class="product-label-link" type="condition" conceptid="4176725" conceptname="Retroperitoneal fibrosis">retroperitoneal fibrosis</span> after long-term use of dihydroergotamine. Extremely rare cases of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> have been reported. A causal relationship has not been established.</p>
<p>D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP is not recommended for prolonged daily use. (<span class="Italics">See <a href="#dosage">DOSAGE AND ADMINISTRATION</a></span>.)</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="ID_ab3c8662-bd33-47be-bf4f-6d8a17a94ad0"></a><a name="section-9"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<p class="First">Currently available data have not demonstrated drug abuse or psychological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> with dihydroergotamine. However, cases of drug abuse and psychological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> in patients on other forms of ergot therapy have been reported. Thus, due to the chronicity of <span class="product-label-link" type="condition" conceptid="4134454" conceptname="Vascular headache">vascular headaches</span>, it is imperative that patients be advised not to exceed recommended dosages.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID_c71f504f-ab6c-4b26-8af8-f4a60e37884b"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">To date, there have been no reports of acute overdosage with this drug. Due to the risk of vascular spasm, exceeding the recommended dosages of D.H.E. 45<span class="Sup">® </span>(dihydroergotamine mesylate) Injection, USP is to be avoided. Excessive doses of dihydroergotamine may result in peripheral signs and symptoms of <span class="product-label-link" type="condition" conceptid="4201303" conceptname="Ergotism">ergotism</span>. Treatment includes discontinuance of the drug, local application of warmth to the affected area, the administration of vasodilators, and nursing care to prevent tissue damage.</p>
<p>In general, the symptoms of an acute D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> are similar to those of an ergotamine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, although there is less pronounced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> with D.H.E. 45<span class="Sup">® </span>(dihydroergotamine mesylate) Injection, USP. The symptoms of an ergotamine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> include the following:  <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, and <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span> of the extremities associated with diminished or absent peripheral pulses; <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>; an increase and/or decrease in blood pressure, usually in that order; <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>; and/or some degree of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>.</p>
<p>In laboratory animals, significant lethality occurs when dihydroergotamine is given at I.V. doses of 44 mg/kg in mice, 130 mg/kg in rats, and 37 mg/kg in rabbits.</p>
<p>Up-to-date information about the treatment of overdosage can often be obtained from a certified Regional Poison Control Center. Telephone numbers of certified Poison Control Centers are listed in the Physician's Desk Reference Book (PDR).</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="dosage"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP should be administered in a dose of 1 mL intravenously, intramuscularly or subcutaneously. The dose can be repeated, as needed, at 1 hour intervals to a total dose of 3 mL for intramuscular or subcutaneous delivery or 2 mL for intravenous delivery in a 24 hour period. The total weekly dosage should not exceed 6 mL. D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP, should not be used for chronic daily administration.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_e0d64d82-a7e1-4dce-97e8-dc2e3ed1a07c"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f0a332f1-5dd8-4805-8f48-f0f40d9cb062"></a><a name="section-12.1"></a><p></p>
<h2>D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP</h2>
<p class="First">Available as a clear, colorless, sterile solution in single 1 mL sterile ampuls containing 1 mg of dihydroergotamine mesylate per mL, in packages of 10 (NDC 66490-041-01).</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="ID_0aa345d0-8045-4666-ae3d-b34618c5c8b5"></a><a name="section-12.2"></a><p></p>
<p class="First">Store below 25°C (77°F), in light-resistant containers.</p>
<p>Do not refrigerate or freeze.</p>
<p>To assure constant potency, protect the ampuls from light and heat. Administer only if clear and colorless.</p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="ID_3f46d41b-291a-4d62-a7ce-7b34c3f8f4f8"></a><a name="section-13"></a><p></p>
<h1>INSTRUCTION FOR PATIENTS ON SUBCUTANEOUS SELF-INJECTION</h1>
<p class="First"><span class="Bold">Information for the Patient</span></p>
<p><span class="Bold">D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP</span></p>
<p>Before self-injecting D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP by subcutaneous administration, you will need to obtain professional instruction on how to properly administer your medication. Below are some of the steps you should follow carefully. Read this leaflet completely before using this medication.</p>
<p>This leaflet does not contain all of the information on D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP. Your pharmacist and/or health care provider can provide more detailed information.</p>
<p><span class="Bold">Purpose of your Medication</span></p>
<p>D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP is intended to treat an active <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span>. Do not try to use it to prevent a <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> if you have no symptoms. Do not use it to treat common <span class="product-label-link" type="condition" conceptid="376382" conceptname="Tension-type headache">tension headache</span> or a <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> that is not at all typical of your usual <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span>. Administration of D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection USP, should not exceed the dosing guidelines and should not be used for chronic daily administration. There have been reports of <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span> (stiffening) in the lung or kidney areas in patients following prolonged daily use of injectable dihydroergotamine mesylate. Rarely, prolonged daily use of other ergot alkaloid drugs (the class of drugs to which D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection USP belongs) has been associated with heart valvular <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span>.</p>
<p>Rare cases have also been reported in association with the use of injectable dihydroergotamine mesylate; however, in those cases, patients also received drugs known to be associated with heart valvular <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span>.</p>
<p><span class="Bold">Do not use D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP if you:</span></p>
<dl>
<dt>•</dt>
<dd>are pregnant or nursing.</dd>
<dt>•</dt>
<dd>have any disease affecting your heart, arteries, or circulation.</dd>
<dt>•</dt>
<dd>are taking certain anti-HIV medications (protease inhibitors).</dd>
<dt>•</dt>
<dd>are taking a macrolide antibiotic such as troleandomycin, clarithromycin or erythromycin.</dd>
</dl>
<p><span class="Bold">Important questions to consider before using </span><br><span class="Bold">D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP</span></p>
<p>Please answer the following questions before you use your D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP.</p>
<p>If you answer YES to any of these questions or are unsure of the answer, you should talk to your doctor before using D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP.</p>
<dl>
<dt>•</dt>
<dd>Do you have high blood pressure?</dd>
<dt>•</dt>
<dd>Do you have <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, heart disease, or have you had any surgery on your heart arteries?</dd>
<dt>•</dt>
<dd>Do you have risk factors for heart disease (such as high blood pressure, high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, smoking, strong family history of heart disease, or you are postmenopausal or a male over 40)?</dd>
<dt>•</dt>
<dd>Do you have any problems with blood circulation in your arms or legs, fingers, or toes?</dd>
<dt>•</dt>
<dd>Are you pregnant? Do you think you might be pregnant? Are you trying to become pregnant? Are you sexually active and not using birth control? Are you breast feeding?</dd>
<dt>•</dt>
<dd>Have you ever had to stop taking this or any other medication because of an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> or bad reaction?</dd>
<dt>•</dt>
<dd>Are you taking any other <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> medications, erythromycin or other antibiotics, or medications for blood pressure prescribed by your doctor, or other medicines obtained from your drugstore without a doctor's prescription?</dd>
<dt>•</dt>
<dd>Do you smoke?</dd>
<dt>•</dt>
<dd>Have you had, or do you have, any disease of the liver or kidney?</dd>
<dt>•</dt>
<dd>Is this <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> different from your usual <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks?</dd>
<dt>•</dt>
<dd>Are you using D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP, nasal spray or other dihydroergotamine mesylate containing drugs on a daily basis?</dd>
<dt>•</dt>
<dd>Are you taking a protease inhibitor for HIV therapy?</dd>
<dt>•</dt>
<dd>Are you taking a macrolide class of antibiotic?</dd>
</dl>
<p>Serious or potentially life-threatening reductions in blood flow to the brain or extremities have been reported rarely due to interactions between D.H.E. 45<span class="Sup">®</span> and protease inhibitors or macrolide antibiotics.</p>
<p><span class="Bold">REMEMBER TO TELL YOUR DOCTOR IF YOU HAVE ANSWERED YES TO ANY OF THESE QUESTIONS BEFORE YOU USE D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP</span></p>
<p><span class="Bold">Side Effects To Watch Out For</span></p>
<p>Although the following reactions rarely occur, they can be serious and should be reported to your physician immediately:</p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Numbness</span> or <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> in your fingers and toes.</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>, tightness, or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> in your chest.</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Muscle pain</span> or <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span> in your arms and legs.</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span> in your legs.</dd>
<dt>•</dt>
<dd>Temporary speeding or slowing of your heart rate.</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">Swelling</span> or <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>.</dd>
</dl>
<p><span class="Bold">Dosage</span></p>
<p>Your doctor will have told you what dose to use for each <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attack. Should you get another <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attack in the same day as the attack you treated, you must not treat it with D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP unless at least 6 hours have elapsed since your last injection. No more than 6 mL of D.H.E. 45<span class="Sup">®</span> (dihydroergotaminemesylate) Injection, USP should be injected during a one-week period. D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP is not intended to be used on a prolonged daily basis.</p>
<p><span class="Bold">Learn what to do in case of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span></span></p>
<p>If you have used more medication than you have been instructed, contact your doctor, hospital emergency department, or nearest poison control center immediately.</p>
<p><span class="Bold">How to use the D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP</span></p>
<dl>
<dt>1.</dt>
<dd>Use available training materials.<dl>
<dt>•</dt>
<dd>Read and follow the instructions in the patient instruction booklet which is provided with the D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP package before attempting to use the product.</dd>
<dt>•</dt>
<dd>If there are any questions concerning the use of your D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP, ask your Doctor or pharmacist.</dd>
</dl>
</dd>
<dt>2.</dt>
<dd>Preparing for the Injection<dl>
<dt>•</dt>
<dd>Carefully examine the ampul (glass vial) of D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP for any cracks or breaks, and the liquid for discoloration, cloudiness, or particles. If any of these defects are present, use a new ampul, make certain it is intact, and return the defective ampul to your doctor or pharmacy. Once you open an ampul, if it is not used within an hour, it should be thrown away.</dd>
</dl>
</dd>
<dt>3.</dt>
<dd>Locating an Injection Site<dl>
<dt>•</dt>
<dd>Administer your subcutaneous injection in the middle of your thigh, well above the knee.</dd>
</dl>
</dd>
<dt>4.</dt>
<dd>Drawing the Medication into the Syringe<dl>
<dt>•</dt>
<dd>A. Wash your hands thoroughly with soap and water.</dd>
<dt>•</dt>
<dd>B. Check the dose of your medication.</dd>
<dt>•</dt>
<dd>C. Look to see if there is any liquid at the top of the ampul. If there is, gently flick the ampul with your finger to get all the liquid into the bottom portion of the ampul.</dd>
<dt>•</dt>
<dd>D. Hold the bottom of the ampul in one hand. Clean the ampul neck with an alcohol wipe using the other hand. To break, place the alcohol wipe around the neck of the ampul and break it open by pressing your thumb against the neck of the ampul.<br><div class="Figure">
<a name="id914"></a><img alt="Instructions for Use" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fe826e6a-75c8-43ed-9c36-f8263ec35aff&amp;name=dhe45-02.jpg">
</div>
</dd>
<dt>•</dt>
<dd>E. Tilt the ampul down at a 45° angle. Insert the needle into the solution in the ampul.</dd>
<dt>•</dt>
<dd>F. Draw up the medication by pulling back the plunger slowly and steadily until you reach your dose.</dd>
<dt>•</dt>
<dd>G. Check the syringe for air bubbles. Hold it with the needle pointing upward. If there are air bubbles, tap your finger against the barrel of the syringe to get the bubbles to the top. Slowly and carefully push the plunger up so that the bubbles are pushed out through the needle and you see a drop of medication.</dd>
<dt>•</dt>
<dd>H. When there are no air bubbles, check the dose of the medication. If the dose is incorrect, repeat steps E, F, G and H until you draw up the right dose.</dd>
</dl>
</dd>
<dt>5.</dt>
<dd>Preparing the Injection Site<dl>
<dt>•</dt>
<dd>With a new alcohol wipe, clean the selected injection site thoroughly with a firm, circular motion from inside to outside. Wait for the injection site to dry before injecting.</dd>
</dl>
</dd>
<dt>6.</dt>
<dd>Administering the Injection<dl>
<dt>•</dt>
<dd>Hold the syringe/needle in your right hand.</dd>
<dt>•</dt>
<dd>With your left hand, firmly grasp about a 1-inch fold of skin at the injection site.</dd>
<dt>•</dt>
<dd>Push the needle shaft, bevel side up, all the way into the fold of skin at a 45° to 90° angle, then release the fold of skin.</dd>
<dt>•</dt>
<dd>While holding the syringe with your left hand, use your right hand to draw back slightly on the plunger.</dd>
<dt>•</dt>
<dd>If you do not see any blood coming back into the syringe, inject the medication by pushing down on the plunger. If you do see blood in the syringe, that means the needle has penetrated a vein. If this happens, pull the needle/syringe out of the skin slightly and draw back on the plunger again. If no blood is seen this time, inject the medication.</dd>
<dt>•</dt>
<dd>Use your right hand to pull the needle out of your skin quickly at the same angle you injected it. Immediately press the alcohol wipe on the injection site and rub.</dd>
</dl>
</dd>
</dl>
<p><span class="Bold">Check the expiration date printed on the ampul containing medication. If the expiration date has passed, do not use it.</span></p>
<p><span class="Bold">Answers to Patients' Questions About D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP</span></p>
<p><span class="Bold">What if I need help in using my D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP?</span></p>
<p>If you have any questions or if you need help in opening, putting together, or using D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP, speak to your doctor or pharmacist.</p>
<p><span class="Bold">How much medication should I use and how often?</span></p>
<p>Your doctor will have told you what dose to use for each <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attack. Should you get another <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attack in the same day as the attack you treated, you must not treat it with D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP unless at least 6 hours have elapsed since your last injection. No more than 6 mL of D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP should be injected during a one-week period. Do not use more than this amount unless instructed to do so by your doctor. D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP is not intended for chronic daily use.</p>
<p>If you have any other unanswered questions about D.H.E. 45<span class="Sup">®</span> (dihydroergotamine mesylate) Injection, USP, consult your doctor or pharmacist.</p>
<p>Manufactured by:<br>DRAXIS Specialty Pharmaceuticals, Inc.<br>16751 Trans-Canada Road<br>Kirkland, Quebec H9H 4J4<br>Canada</p>
<p>Manufactured for:<br>Valeant Pharmaceuticals North America<br>Aliso Viejo, CA 92656<br>U.S.A.</p>
<p>212771</p>
<p>Rev. 09/09</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_e5b207a2-24b1-45a1-9f64-6d0ac598d7a2"></a><a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 1 mL ampul Carton</h1>
<p class="First"><span class="Bold">NDC 66490-041-01</span><br><span class="Bold">Rx Only</span></p>
<p><span class="Bold">D.H.E. 45<span class="Sup">®</span></span><br><span class="Italics">(dihydroergotamine mesylate) injection, USP</span></p>
<p><span class="Bold">1 mg/mL</span> (1 mL ampul)</p>
<p>FOR I.V., I.M. or S.C. USE</p>
<p><span class="Bold">10 × 1 mL ampuls</span><br><span class="Bold">Unit Dose Package</span></p>
<p>VALEANT<span class="Sup">®</span><br>Pharmaceuticals North America</p>
<div class="Figure">
<a name="id991"></a><img alt="Principal Display Panel - 1 mL ampul Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fe826e6a-75c8-43ed-9c36-f8263ec35aff&amp;name=dhe45-03.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>D.H.E. 45 		
					</strong><br><span class="contentTableReg">dihydroergotamine mesylate injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:66490-041</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Dihydroergotamine Mesylate</strong> (Dihydroergotamine) </td>
<td class="formItem">Dihydroergotamine Mesylate</td>
<td class="formItem">1 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Glycerin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Methanesulfonic Acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium Hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:66490-041-01</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 AMPULE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA005929</td>
<td class="formItem">10/03/2001</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Valeant Pharmaceuticals North America
							(831922468)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Jubilant HollisterStier General Partnership</td>
<td class="formItem"></td>
<td class="formItem">246762764</td>
<td class="formItem">MANUFACTURE(66490-041)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>e5d790c0-7211-46d7-bde6-ddb4130888d3</div>
<div>Set id: fe826e6a-75c8-43ed-9c36-f8263ec35aff</div>
<div>Version: 5</div>
<div>Effective Time: 20141230</div>
</div>
</div> <div class="DistributorName">Valeant Pharmaceuticals North America</div></p>
</body></html>
